[go: up one dir, main page]

MX2023002619A - Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico. - Google Patents

Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico.

Info

Publication number
MX2023002619A
MX2023002619A MX2023002619A MX2023002619A MX2023002619A MX 2023002619 A MX2023002619 A MX 2023002619A MX 2023002619 A MX2023002619 A MX 2023002619A MX 2023002619 A MX2023002619 A MX 2023002619A MX 2023002619 A MX2023002619 A MX 2023002619A
Authority
MX
Mexico
Prior art keywords
sub
nitrated
psilocybin
alkyl
group
Prior art date
Application number
MX2023002619A
Other languages
English (en)
Inventor
Jillian M Hagel
Peter J Facchini
Chang- Chun LING
Original Assignee
Enveric Biosciences Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveric Biosciences Canada Inc filed Critical Enveric Biosciences Canada Inc
Publication of MX2023002619A publication Critical patent/MX2023002619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01005—Arylamine N-acetyltransferase (2.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a describir nuevos compuestos derivados de la psilocibina nitrada y formulaciones de fármacos recreativos y farmacéuticos que contienen los mismos. Los compuestos derivados de psilocibina nitrados pueden sintetizarse químicamente o sintetizarse bioquímicamente en células huésped.
MX2023002619A 2020-09-02 2021-09-02 Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico. MX2023002619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (1)

Publication Number Publication Date
MX2023002619A true MX2023002619A (es) 2023-04-10

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002619A MX2023002619A (es) 2020-09-02 2021-09-02 Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico.

Country Status (10)

Country Link
US (1) US20230040398A1 (es)
EP (1) EP4208446A4 (es)
JP (1) JP2023539390A (es)
KR (1) KR20230061473A (es)
CN (1) CN116782896A (es)
AU (1) AU2021336667A1 (es)
CA (1) CA3191095A1 (es)
IL (1) IL301028A (es)
MX (1) MX2023002619A (es)
WO (1) WO2022047583A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020358720A1 (en) 2019-10-01 2022-04-21 Empyrean Neuroscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
EP4291549A4 (en) * 2021-02-12 2025-01-22 Enveric Biosciences Canada Inc. MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
US12060328B2 (en) 2022-03-04 2024-08-13 Reset Pharmaceuticals, Inc. Co-crystals or salts of psilocybin and methods of treatment therewith
CA3246235A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
US11746087B1 (en) 2022-03-18 2023-09-05 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
JP2025539131A (ja) 2022-11-18 2025-12-03 エンベリック バイオサイエンシズ カナダ インコーポレイテッド 置換ｎ－プロピルアミン縮合複素環メスカリン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
AU2001280984A1 (en) * 2000-07-28 2002-02-13 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
DK1379239T3 (da) * 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
EP3119406B1 (en) * 2014-03-18 2021-01-20 Carmel-Haifa University Economic Corporation Ltd Methods for improving cognitive function via modulation of quinone reductase 2
US11078467B2 (en) * 2016-10-26 2021-08-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Also Published As

Publication number Publication date
IL301028A (en) 2023-05-01
KR20230061473A (ko) 2023-05-08
AU2021336667A8 (en) 2023-04-13
AU2021336667A1 (en) 2023-03-30
US20230040398A1 (en) 2023-02-09
JP2023539390A (ja) 2023-09-13
CN116782896A (zh) 2023-09-19
WO2022047583A1 (en) 2022-03-10
EP4208446A4 (en) 2024-10-30
CA3191095A1 (en) 2022-03-10
EP4208446A1 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
MX2023002619A (es) Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
ES483700A1 (es) Un procedimiento para preparar 2-nitroimidazols.
KR870006072A (ko) 라파마이신 전구체의 제조방법
ATE14579T1 (de) Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
NZ242243A (en) 2-substituted adenine triphosphate derivatives and pharmaceutical compositions
ES8706608A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
ES269967A1 (es) Un procedimiento para la preparaciën de pirazolonas sustituidas
BG104933A (en) Water soluble azoles and broad-spectrum antifungals
GB1291675A (en) 0-(1,3,4-thiadiazol-2-yl)-imidazolidinone(2) derivatives, process for their production and their use as herbicidal agents
NZ333705A (en) Furan nitrone derivatives and medicaments thereof
DE60027034D1 (de) 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
SE7614265L (sv) Beta-lactamantibiotika
ATE1063T1 (de) Neue 1-(2-halogenaethyl)-1-nitrosoharnstoffe und deren herstellung.
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
ES472877A1 (es) Procedimiento para preparar derivados de 25-alquilcolesterol
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
NZ508852A (en) 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use in treating CNS and circulation disorders
ES8106725A1 (es) Procedimiento de preparar derivados 1,2,4-oxadiazolin-5-oni-cos
ES8201140A1 (es) Procedimiento para la preparacion de 2-fenilamino-imidazoli nas-(2)sustituidas.
ES8200692A1 (es) Procedimiento para la preparacion de nuevas cefalosporinas
ES8201977A1 (es) Procedimiento de preparacion de aminoalcoxipirazoles
ES8801637A1 (es) Un procedimiento para la preparacion de benzimidazoles.
PT1189908E (pt) Alcaloides de indolocarbazole de um actinomiceto marinho
ES8106537A1 (es) Procedimiento de preparacion de nuevos fosfatos de n-(fenilosubstituido)-n-(alcoxicarbonilalcohil)-acetamidas